---
title: "Gubra earns USD 50 million milestone as AbbVie starts Phase 2 trial of obesity drug ABBV-295"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297036149.md"
description: "Gubra announced that AbbVie has initiated a Phase 2 trial for its obesity drug candidate ABBV-295, triggering a $50 million milestone payment. This follows promising Phase 1 results showing weight loss potential with acceptable safety. The new study will evaluate multiple dosing approaches in adults with obesity or overweight. ABBV-295 targets amylin, offering a distinct mechanism from GLP-1 or GIP-based drugs. Under the 2025 license deal, Gubra remains eligible for up to $1.875 billion in additional milestones and tiered royalties."
datetime: "2026-08-26T11:24:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297036149.md)
  - [en](https://longbridge.com/en/news/297036149.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297036149.md)
generator: "portal-rs"
---

# Gubra earns USD 50 million milestone as AbbVie starts Phase 2 trial of obesity drug ABBV-295

-   Gubra disclosed AbbVie has started a Phase 2 trial of obesity drug candidate ABBV-295, triggering a USD 50 million milestone payment. \* Earlier Phase 1 results have already been presented, indicating weight loss potential with acceptable safety and tolerability. \* The Phase 2 study will test multiple dosing approaches in adults with obesity or overweight, with efficacy readouts expected later. \* ABBV-295 targets amylin, positioning it as a distinct mechanism from GLP-1 or GIP-based weight-loss drugs. \* The 2025 license deal leaves Gubra eligible for up to USD 1.875 billion in milestones, plus tiered royalties on global net sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)

## Related News & Research

- [If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/297083612.md)
- [Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?](https://longbridge.com/en/news/296816441.md)
- [Massachusetts Financial Services Co. MA Reduces Stock Position in AbbVie Inc. $ABBV](https://longbridge.com/en/news/296592574.md)
- [Vest Financial LLC Sells 3,946 Shares of AbbVie Inc. $ABBV](https://longbridge.com/en/news/296462167.md)
- [Focus Partners Advisor Solutions LLC Boosts Position in AbbVie Inc. $ABBV](https://longbridge.com/en/news/297140864.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**